Fibronectin and fibrinogen degradation products stimulate PMN-leukocyte and mast cell degranulation

• Autorzy: Wojtecka-Lukasik E , Maslinski S.
• Języki publikacji: EN

Abstrakty

EN

The ability of various peptides cleaved by plasmin from human fibrinogen and fibronectin or fibrinogen- and fibronectin- related synthetic peptides to induce histamine release from mast cells and collagenase and elastase from PMN- leukocytes was examined. Low molecular weight fibrinogen degradation products showed dose dependent secretion of collagenase. These peptides (mol. wt. 1.4 kD) at the concentration of 10⁻⁵ M released about 47% of collagenase and 13% of elastase. Synthetic fib- rinopeptides A and В had a similar strong collagenase releasing potency and also released histamine from mast cells. Peptides from plasmin digestion of fibronectin containing cell attachment site with sequence Arg-Gly-Asp-Ser and also synthetic peptide reproducing this aminoacid sequence at the concentration of 1000 µg/ml released about 50% of collagenase and 55% of elastase from PMN-leukocytes. Moreover peptides containing cell attachment and gelatin binding site induced histamine release from mast cells. The association of fibrinogen and fibronectin degradation with activation of mast cells may motivate the treatment with antihistaminic drugs of all pathological conditions where the intensive protein degradation takes place.

Słowa kluczowe

EN

histamine; degranulation; mast cell; plasma; collagenase; fibrinogen degradation product; fibronectin; leucocyte

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 1992
• Tom: 43
• Numer: 2
• Opis fizyczny: p.173-181,fig.

Twórcy

autor

Wojtecka-Lukasik E

• Institute of Rheumatology, 02-637 Warsaw, Spartanska 1, Poland

autor

Maslinski S.

Bibliografia

• 1. Vartio T, Vahen A, DePetro G, Berlati S, Fibronectin and its proteolytic fragments potential as cancer markers. Invasion Metastasis 1983; 3: 125-138.
• 2. Lohr KM, Kurth CA, Dong-Lin Xie, Seyer JM, Homandberg GA. The aminoterminal 29-and 72 kD fragments of fibronectin mediate selective monocyte recruitment. Blood 1990; 76/10: 2117-2124.
• 3. Taukamoto Y, Helsel WE, Wahl SM. Macrophage production of fibronectin a chemoattractant for fibroblasts. J Immunol 1981; 127: 673-682.
• 4. Bowersox JC, Sorgente N. Chemotactic response of vascular endothelial cells to fibronectin. J Cell Biol 1980; 87: 64-71.
• 5. Wachtfogel YT, Abrams W, Kucich U, Wanbaum G, Schapira M. Fibronectin degradation products containing the cytoadhesive tetrapeptide stimulate human neutrophil degranulation. J Clin Invest 1988; 81: 1310-1316.
• 6. Stachurska J, Łopaciuk J, Gerdin B, Saldeen T, Korościk A, Kopeć M. Effects of proteolytic degradation products of human fibrinogen and human factor VIII on platelet aggregation and vascular permeability. Thrombosis et Diathesis Haemorrhagie 1979; 15: 663.
• 7. Richardson DL, Pepper DS, Kay AB. Chemotaxis for human monocytes by fibrinogen derived peptides. Br J Haematol 1979; 32: 507-513.
• 8. Edgington TS, Curtiss LK, Plow ET. A linkage between the hemostatic and immune systems embodied in the fibrinolytic release of lymphocyte suppressive peptides. J Immunol 1985; 134: 471-476.
• 9. Stachurska J, Janik M, Kobus M. Effects of peptides cleaved from human fibrinogen by plasmin on rabbit kidney cells culture. Thromb Res 1983; 25: 419-424.
• 10. Buczko M, Moniuszko-Jakoniuk J. Influence of fibrinogen degradation products (FDP) on the central nervous system and on the effect on centrally acting drugs. Pharmacology 1975; 13: 252-257.
• 11. Yamada KM. Isolation of fibronectin from plasma and cells. In Immunochemistry of the Extracellular Matrix, JH Furthmayer (ed). Florida, CRC Press Boca Raton, 1985; 1: pp. 111-123
• 12. Alm PE. Sodium fluoride evoked histamine release from mast cells. A study on cyclic AMP levels and effects of catecholamines. Agents Actions 1983; 13: 132-138.
• 13. Shore PA, Burkhalter A, Cohn VH. A method for the fluorimetric assay of histamine m tissues. J Pharmacol Exp Ther 1959; 127: 182-186.
• 14. Wojtecka-Łukasik E, Dancewicz AM. Inhibition of human leukocyte collagenase by some drugs used in theraphy of rheumatoid diseases. Biochem Pharmacol 1974; 23: 2077-2081.
• 15. Visser L, Blout ER. The use p-nitrophenyl N-tert butyloxycarbonyl-L-alanine as a substrate for elastase. Biochim Biophys Acta 1972; 268: 257-268.
• 16. Pierchbacher MD, Ruoslahti I. The cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature (bond.) 1984; 309: 30-33.
• 17. Vaheri A, Vartio T, Stenmans S, Saksela O, Hedmans K, Alitalo K. Fibronectin and proteinases in tumor invasion. In Proteinases and Tumor Invasion, P. Barret, AJ Baici (eds). New York, NY Raven, 1980, pp. 49-61.
• 18. Carsons S, Lavieties BB, Diamond H, Kinney SG. The immunoreactivity, ligand and cell binding characteristics of rheumatoid synovial fluid fibronectin. Arthritis Rheum 1985; 28/6: 601-612.
• 19. Homanberg GA, Williams JE, Schumacher B, Grant D, Eisenstein R. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Pathol 1985; 120: 327-332.
• 20. De Petro G, Barlat S, Vartio T, Vaheri A. Transformation enhancing activity of gelatinbinding fragments of fibronectin. Proc Natl Acad Sci USA 1981; 78: 4965-4973.
• 21. Yamada K, Kennedy DW. Dualistic nature of adhesive protein function. Fibronectin and its biologically active peptide fragments can autoinhibit fibronectin function. J Cell Biol 1984; 99: 29-36.
• 22. Ruhenstroth-Bauer G, Scherer R, Hornberger M, Tongendorff G. Demonstration of antiinflammatory activity of fibrinogen and fibrinopeptides in rats. Inflammation 1981; 5/4: 343-351.
• 23. Erikson M, Saldeen В, Saldeen T, Stranberg R. Fibrinderived vasoactive peptides release histamine. Int J Microcirc Clin Exp 1983; 2: 337-345.
• 24. Wojtecka-Łukasik E, Maśliński S. Histamine, 5-hydroxytryptamine and compound 48/80 activate PMN-leukocyte collagenase of rats. Agents and Actions 1984; 14, 3/4: 451-453.
• 25. Wojtecka-Łukasik E, Stachurska J, Kopeć M, Maśliński S. Anti-inflammatory drugs modulate histamine release from mast cells induced by fibrinogen degradation products. Ann Rheum Dis 1988; 47: 328-332.